Click Here for 5% Off Your First Aladdin Purchase!

Utomilumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG2SA, Antibody of 4-1BB

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Application: ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG2SA
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab170652
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab170652-100μg
100μg
In stock
$79.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameUtomilumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG2SA
Synonyms4 1BB antibody; 4 1BB ligand receptor antibody; 4-1BB ligand receptor antibody; 4-1BB Ligand Receptor T Cell antibody; 4-1BB, mouse, homolog of antibody; Antigen 4-1BB Homolog antibody; CD 137 antibody; CD137 antibody; CD137 antigen antibody; CDw137 antib
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityTNFRSF9
ApplicationELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeAGONIST
Mechanism of actionAntibody of 4-1BB
Product Description

PurityUtomilumab is a humanized IgG2 mAb agonist that targets the T-cell co-stimulatory receptor 4-1BB/CD137. Utomilumab can be used in relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphoma (NHL) studies.
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Antibody TypePrimary antibody
ClonalityRecombinant
IsotypeHuman IgG2SA
Light Chain Typelambda C2
SDS-PAGE28.6 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 171.1 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
SourceCHO supernatant
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1417318-27-4

Images

Utomilumab (anti-TNFRSF9) (Ab170652) - ELISA
Immobilized Human TNFRSF9/ 4-1BB/ CD137-his at 2.0 μg/mL can bind Utomilumab (anti-TNFRSF9) (Ab170652) with the EC₅₀ of 6.92 ng/mL.

Utomilumab (anti-TNFRSF9) (Ab170652) - SEC
The purity of Utomilumab (anti-TNFRSF9) (Ab170652) is more than 95% verified by HPLC.

Associated Targets

TNFRSF9 Tbio Tumor necrosis factor receptor superfamily member 9 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303717Certificate of AnalysisMar 26, 2024 Ab170652
ZJ24F0303716Certificate of AnalysisMar 26, 2024 Ab170652
ZJ24F0303715Certificate of AnalysisMar 26, 2024 Ab170652

Related Documents

References

1. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC et al..  (2012)  Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity..  Cancer Immunol Immunother,  61  (10): (1721-33).  [PMID:22406983]
2. Mittal P, Abblett R, Ryan JM, Hagymasi AT, Agyekum-Yamoah A, Svedova J, Reiner SL, St Rose MC, Hanley MP, Vella AT et al..  (2018)  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells..  J Immunol,  200  (4): (1513-1526).  [PMID:29305435]
3. Zhou, Z Z and 6 more authors..  (1995)  Characterization of human homologue of 4-1BB and its ligand..  Immunology letters,      [PMID:7622190]
4. Alderson, M R MR and 9 more authors..  (1994)  Molecular and biological characterization of human 4-1BB and its ligand..  European journal of immunology,      [PMID:8088337]
5. Schwarz, H H, Tuckwell, J J and Lotz, M M..  (1993)  A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family..  Gene,    (8):   [PMID:8262389]
6. Jang, L K LK and 5 more authors..  (2001)  A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction..  Molecules and cells,    (31):   [PMID:11804328]
7. Saoulli, K K and 10 more authors..  (1998)  CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand..  The Journal of experimental medicine,    (1):   [PMID:9607925]

Solution Calculators